Links

Tools

Export citation

Search in Google Scholar

Biological, clinical and population relevance of 95 loci for blood lipids

Journal article published in 2010 by Tanya M. (Tanya) Teslovich, K. (Kiran) Musunuru, Av Smith, Albert V. (Albert Vernon) Smith ORCID, Andrew C. (Andrew) Edmondson, Ioannis M. (Ioannis) Stylianou, M. (Masahiro) Koseki, J.-A. (John-Anker) Zwart, James P. (James) Pirruccello, S. (Samuli) Ripatti, Daniel I. (Daniel) Chasman, Cristen J. (Cristen) Willer, M. (maja) Barbalic, Christopher T. (Christopher) Johansen, Aaron J. (Aaron) Isaacs and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

Plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides are among the most important risk factors for coronary artery disease (CAD) and are targets for therapeutic intervention. We screened the genome for common variants associated with plasma lipids in >100,000 individuals of European ancestry. Here we report 95 significantly associated loci (P < 5 x 10(-8)), with 59 showing genome-wide significant association with lipid traits for the first time. The newly reported associations include single nucleotide polymorphisms (SNPs) near known lipid regulators (for example, CYP7A1, NPC1L1 and SCARB1) as well as in scores of loci not previously implicated in lipoprotein metabolism. The 95 loci contribute not only to normal variation in lipid traits but also to extreme lipid phenotypes and have an impact on lipid traits in three non-European populations (East Asians, South Asians and African Americans). Our results identify several novel loci associated with plasma lipids that are also associated with CAD. Finally, we validated three of the novel genes-GALNT2, PPP1R3B and TTC39B-with experiments in mouse models. Taken together, our findings provide the foundation to develop a broader biological understanding of lipoprotein metabolism and to identify new therapeutic opportunities for the prevention of CAD.